Mobia Medical Revenue Rises 73% in Q3; Raises 2026 Guidance
Revenue increased to $15.6 million, while full-year 2026 revenue guidance rose to $57.0 million–$57.5 million from $54.0 million–$56.0 million.
Mobia Medical, Inc. announced its financial results for the third quarter ended September 30, 2026, highlighting a 73% increase in revenue to $15.6 million compared to the same period in 2025. The company's gross profit rose 81% to $13.0 million, with a gross margin of 83.2%. Driven by strong commercial performance and broader adoption of the Vivistim Paired VNS System, the company raised its full-year 2026 revenue guidance to a range of $57.0 million to $57.5 million, up from its previous forecast of $54.0 million to $56.0 million.
Operating expenses increased by 71% to $31.5 million as the company continues to invest in its commercial organization to support growth. As of September 30, 2026, the company reported cash and cash equivalents of $160.7 million.